# Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

> **NCT02013531** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Major Depressive Disorder
- Anxiety

## Interventions

- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT02013531
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013531, "Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02013531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*